Nuron Biotech Acquires Vaccine from Pfizer
The vaccine prevents meningitis, sepsis and pneumonia
Nuron Biotech Inc. has acquired Meningitec, a meningitis vaccine, from Pfizer Inc. (NYSE: PFE) for an undisclosed amount.
The vaccine prevents diseases, such as meningitis, sepsis and pneumonia, caused by Neisseria meningitides. It is available in 23 countries, including France, Germany and Australia.
Nuron Biotech, based in Exton, Pa., develops vaccines to prevent neurodegenerative and infectious diseases.
Pfizer, based in New York, is a pharmaceutical company. In November, it closed on a purchase of NextWave Pharmaceuticals Inc., and in April, it sold off its infant-nutrition business to Nestle SA for $11.85 billion.
For more information on related topics, visit the following: